This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Surgery  • Surgical Interventions  • Endocrine Surgery  • Transplantation  • Transplantation, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;301(15):1521-1525.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Nearly a decade ago, promising results from a clinical trial demonstrating that patients who received pancreatic islet cell transplants could become insulin independent stoked hope that islet cell transplantation might one day cure type 1 diabetes.

Since then, however, such optimism has been tempered by less promising long-term results, as well as substantial costs and questions about the therapy's safety and utility. Some scientists who are working on refinements that would promote long-term insulin independence say they still see great promise in the islet transplantation—and preliminary clinical studies are putting some recent refinements to the test. But others have questioned whether clinical studies should be scaled back.

"The field is advancing very quickly and carries a lot of promise," said Michael C. Appel, PhD, director of the Islet Biology and Transplantation Research Program at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). But because . . . [Full Text of this Article]

EDMONTON TRIALS



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?